Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Benzylpenicillin Concentrations in Intrapartum Group B Streptococcus Prevention Guidelines; A Systematic Review of the Evidence.

The Australian & New Zealand journal of obstetrics & gynaecology·2026
Same author

Achieving therapeutic antibiotic levels during intermittent dosing of meropenem and piperacillin-tazobactam in critically ill children: the ATACC study.

Antimicrobial agents and chemotherapy·2026
Same author

Using an RNA binding protein to detect mRNA on lipid nanoparticles.

Scientific reports·2026
Same author

Rare coding variant architecture and gene discovery from 130,000 sequenced cases of atrial fibrillation.

Research square·2026
Same author

Intrapulmonary penetration of ceftolozane/tazobactam and ceftazidime/avibactam administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial.

Critical care (London, England)·2026
Same author

Early adequate linezolid concentrations and clinical outcomes in confirmed Gram-positive infections: the role of therapeutic drug monitoring.

The Journal of antimicrobial chemotherapy·2026

相关实验视频

Updated: Jun 27, 2026

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

21.8K

开发生产SARS CoV-2病毒样颗粒规模生产方法.

Melissa A Edeling1, Linda Earnest1, Julio Carrera Montoya1

  • 1Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.

Biotechnology and bioengineering
|February 12, 2025
PubMed
概括

研究人员开发了一种快速,可扩展的方法来产生SARS-CoV-2病毒样颗粒 (VLPs) 以防范流行病. 这种高效的工艺确保了VLP疫苗和治疗药物的快速制造.

关键词:
根据COVID-19的情况,在SARS-CoV-2中.这就是VLP的VLP.分子平台 分子平台蛋白质净化 蛋白质净化可扩展性可扩展性.疫苗 疫苗 疫苗 疫苗类似病毒的颗粒.

更多相关视频

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
08:40

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

58.9K
Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses
08:10

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

8.2K

相关实验视频

Last Updated: Jun 27, 2026

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

21.8K
Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
08:40

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

58.9K
Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses
08:10

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

8.2K

科学领域:

  • 生物技术是生物技术.
  • 病毒学 病毒学
  • 疫苗开发 疫苗开发

背景情况:

  • SARS-CoV-2 疫情凸显了急需快速开发医疗对策的迫切需要.
  • 现有的疫苗平台需要很长的时间来开发和制造,这给疫情防控带来了挑战.

研究的目的:

  • 建立一种简单,高效和可扩展的过程,用于生产SARS-CoV-2病毒样颗粒 (VLPs).
  • 创建一个分子平台,在流行病期间快速制造医疗干预措施.

主要方法:

  • 使用100kDa半透膜进行接触式流量过,用于度和缓冲区交换.
  • 交换色谱用于VLP净化.
  • 使用西斑,ELISA和电子显微镜进行质量控制,以确认VLP完整性和Spike蛋白的存在.

主要成果:

  • 在不到2天的时间内完成了SARS-CoV-2 VLP的净化.
  • 证明了VLP的成功缩,净化和质量控制.
  • 通过多种分析技术验证了VLP结构和Spike蛋白显示.

结论:

  • 描述的VLP生产过程是适应和可扩展的制造.
  • 这种方法作为生产临床前研究和未来流行病准备的VLP的路线图.
  • 快速VLP生产对于及时应对新出现的传染病至关重要.